ScienceDex / Researcher record
Su, Guowei
- Glycan Therapeutics Corporation (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
- Early Career
NIH Funding · FY2023
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2021 | $968,047 | 1 | #9,712 |
| 2022 | $331,634 | 1 | #32,771 |
| 2023 | $605,001 | 2 | #20,058 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20211 record
- FY20221 record
- FY2023 · selected2 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2021 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2023 award records by amount
NIH award records listing Su, Guowei as a PI. Multi-PI records show the full award amount for context.
- 1R43GM149008-01R43Contact PIDevelopment of a sensitive method to measure heparan sulfate 6-O-endosulfatase$350Kaward amount
- 1R44GM145004-01A1R44Contact PISynthesis of the library of heparan sulfate hexasaccharide mimetics$255Kaward amount
Award organization
Organizations that administered FY2023 awards listing Su, Guowei as a PI.
FY2023 award administered by Glycan Therapeutics Corporation (NC).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2021First NIH AwardGlycan Therapeutics Corporation
- 2021$500K Cumulative Funding
- 2021Entered Top 50% NationallyRanked #9712
- 2022$1M Cumulative Funding